Fig. 3

Maximum Symptom Severity at Exit DBPCFC in PALISADE by SOC. A Respiratory symptoms. B Gastrointestinal symptoms. C Cardiovascular/neurological symptoms. D Dermatological symptoms. Maximum severity was assessed at any dose of peanut protein in the exit DBPCFC by SOC in the PALISADE trial within the PTAH-treated and the placebo-treated participants. ^aRR for symptoms of any severity, PTAH vs placebo. CI confidence interval, DBPCFC double-blind, placebo-controlled food challenge, PTAH peanut (Arachis hypogaea) allergen powder-dnfp, RR relative risk, SOC system organ class